Astria Therapeutics Inc (ATXS)

Ticker: ATXS Exchange: NMS


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Astria Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Planned sale 1 Apr 2024
Value US$4,112,102.91 | Price 16.66 | Shares 55,191 (-36.4%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2024-04-03 2024-04-01 PlS Planned sale

Chief Medical Officer

Officer
55,191 -36.4%
16.66
US$4,112,103
55,191 -36.4% 16.66 US$4,112,103
2024-04-01 2024-04-01 PrS Proposed sale

Officer

Officer
52,016
453.22
US$3,401,856
52,016 453.22 US$3,401,856
2024-02-05 2024-02-01 B Purchase Non-Executive Director
87,070 -43.1%
435.14
US$1,289,623
87,070 -43.1% 435.14 US$1,289,623
2024-01-30 2024-01-29 PlS Planned sale

Chief Medical Officer

Officer
9,200 -100.0%
11.15
US$102,552
9,200 -100.0% 11.15 US$102,552
2024-01-29 2024-01-29 PrS Proposed sale

Officer

Officer
9,200
11.15
US$102,552
9,200 11.15 US$102,552
2024-01-30 2024-01-26 PlS Planned sale

Chief Medical Officer

Officer
800 -100.0%
11.02
US$8,812
800 -100.0% 11.02 US$8,812
2023-12-22 2023-12-21 B Purchase Non-Executive Director
740,000 +44.8%
6.20
US$4,588,000
740,000 +44.8% 6.20 US$4,588,000
2023-10-18 2023-10-16 B Purchase Non-Executive Director
460,546 +40.0%
6.51
US$2,999,997
460,546 +40.0% 6.51 US$2,999,997
2023-10-18 2023-10-16 B Purchase Non-Executive Director
614,062 +59.1%
6.51
US$4,000,000
614,062 +59.1% 6.51 US$4,000,000
2022-12-21 2022-12-19 B Purchase Non-Executive Director
908,265 +698.4%
11.01
US$9,999,998
908,265 +698.4% 11.01 US$9,999,998
2021-11-23 2021-11-19 B Purchase

Chief Commercial Officer

Officer
100 +inf%
6.70
US$670
100 +inf% 6.70 US$670
2015-06-30 2015-06-30 B Purchase George Jean Non-Executive Director
12,422 +15.9%
12.00
US$149,064
12,422 +15.9% 12.00 US$149,064
2015-06-30 2015-06-30 B Purchase George Jean Non-Executive Director
91,166 +15.9%
12.00
US$1,093,992
91,166 +15.9% 12.00 US$1,093,992
2015-06-30 2015-06-30 B Purchase George Jean Non-Executive Director
155,188 +15.9%
12.00
US$1,862,256
155,188 +15.9% 12.00 US$1,862,256
2015-06-30 2015-06-30 B Purchase GALAKATOS NICHOLAS Non-Executive Director Large shareholder
376,695 +15.9%
12.00
US$4,520,340
376,695 +15.9% 12.00 US$4,520,340
2015-06-30 2015-06-30 B Purchase Laufer Ron Non-Executive Director Large shareholder
223,439 +15.9%
12.00
US$2,681,268
223,439 +15.9% 12.00 US$2,681,268
2015-06-30 2015-06-30 B Purchase SVLSF V, LLC Large shareholder
8,094 +15.9%
12.00
US$97,128
8,094 +15.9% 12.00 US$97,128
2015-06-30 2015-06-30 B Purchase SVLSF V, LLC Large shareholder
382,996 +15.9%
12.00
US$4,595,952
382,996 +15.9% 12.00 US$4,595,952
2015-06-30 2015-06-30 B Purchase Clarus Lifesciences II, L.P. Large shareholder
376,695 +15.9%
12.00
US$4,520,340
376,695 +15.9% 12.00 US$4,520,340
2015-06-30 2015-06-30 B Purchase MedImmune Ventures, Inc. Large shareholder
223,439 +15.9%
12.00
US$2,681,268
223,439 +15.9% 12.00 US$2,681,268